-33%

IPAMORELIN 5 mg

Original price was: 29,99 €.Current price is: 19,99 €. with VAT

Ipamorelin is a synthetic pentapeptide with exceptional selectivity among GH secretagogues: unlike GHRP-2 or GHRP-6, it does not increase cortisol or prolactin levels in preclinical studies. This is precisely why it is one of the most extensively studied GH peptides in endocrinology.

Purity ≥ 98% – Each batch verified by HPLC; COA available upon request
5 mg of lyophilized powder, stable for 24 months at −20 °C
Shipped within 48 hours

In stock

Dosage calculator

Quantity discount

Quantity	Price	% Discount
7+	17,99 €	10%
4+	18,99 €	5%

Category: Research on muscle growth Tags: Fitness & Bodybuilding, Ipamorelin

All products are sold exclusively for the purpose of scientific research and development.
The chemical substances may not be used as a medicine, drug, active substance, medical device, cosmetic product, substance for the manufacture of a cosmetic product, or as a substance for human consumption, i.e. as a food or nutritional supplement, or in any other similar way on humans or animals.

All customers MUST be at least 18 years of age to purchase our products.

Laboratory-tested

Fast and Discreet Shipping

Purity Guarantee

98%+

Description

Ipamorelin 5 mg – Selective GH Secretagogue for Scientific Research

⚠️ Legal Notice: Ipamorelin is intended exclusively for scientific and research purposes. It is not intended for human use as a medication, dietary supplement, or cosmetic product. Sale restricted to individuals over the age of 18.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide —a compound consisting of five amino acids with the amino acid sequence Aib-His-D-2Nal-D-Phe-Lys-NH₂. It was derived from research on GHRP-1 and belongs to the group of growth hormone secretagogues (GHS—Growth Hormone Secretagogues).
Ipamorelin is characterized by exceptional selectivity within the group of growth hormone secretagogues. While related compounds such as GHRP-2 or GHRP-6 increase not only GH levels but also cortisol and prolactin at research dosages, Ipamorelin does not exhibit these hormonal side effects in preclinical studies. It is precisely this selectivity that makes Ipamorelin one of the most extensively studied GH peptides in the field of endocrinology.
Important: Ipamorelin is not approved as a drug in the European Union or in other jurisdictions. All available data come from preclinical studies (in vitro and in vivo in animal models).

Mechanism of Action in Research

Selective activation of GHS-R1a—without cortisol or prolactin

Ipamorelin acts as a selective agonist of the ghrelin receptor GHS-R1a in the anterior pituitary and hypothalamus. By activating this receptor, it stimulates the pulsatile release of growth hormone from somatotrophic cells in the anterior pituitary.
A key research characteristic of Ipamorelin lies in its selectivity: preclinical studies and controlled clinical research protocols consistently demonstrate that, at typically tested doses, Ipamorelin does not increase levels of cortisol (adrenal cortex glucocorticoids) or prolactin (a pituitary hormone). This property stands in direct contrast to GHRP-2 and GHRP-6, both of which increase these hormones.
Selective action on GHS-R1a without activating the pathways responsible for cortisol/prolactin release allows researchers to study GH secretion in isolation, free from the confounding effects of the HPA axis (hypothalamic-pituitary-adrenal).
Source: Raun K. et al., European Journal of Endocrinology (1998); Bowers CY., Endocrine (1998)

Comparison of Selectivity: Ipamorelin vs. GHRP-2 vs. GHRP-6

Property	Ipamorelin	GHRP-2	GHRP-6
Peptide Type	Pentapeptide	Hexapeptide	Hexapeptide
Receptor	GHS-R1a	GHS-R1a	GHS-R1a
GH Release Intensity	Moderate–strong	Strong	Strong
Effect on Cortisol	None/minimal	Increase	Increase
Effect on prolactin	None/minimal	Increase	Increase
Effect on Appetite	Minimal	Mild	Significant
Selectivity for GH	High	Low	Low

Note: This table summarizes the results of preclinical research and is not intended to provide clinical recommendations.

The Synergistic Combination of Ipamorelin and CJC-1295 in Research

One of the most extensively studied combinations in the field of GH peptides is the combination of Ipamorelin (a GHS-R1a agonist) with CJC-1295 or Modified GRF 1-29 (a GHRH analog). These two classes of compounds act through different receptors and independent signaling pathways.
GHRH analogs (CJC-1295, Modified GRF 1-29) activate the GHRH-R receptor on somatotrophs, thereby increasing their sensitivity to further stimuli. Ipamorelin simultaneously activates GHS-R1a. According to preclinical studies in animal models, this results in an amplified GH pulse —a more pronounced increase in GH secretion compared to the administration of each compound alone.
This synergistic interaction is of scientific interest because it reflects the natural mechanism by which GH secretion is regulated in vivo: the hypothalamus releases both GHRH and ghrelin (an endogenous ligand for GHS-R1a) simultaneously, and their combined effect is stronger than the sum of their individual effects.
Source: Khorram O. et al., Journal of Clinical Endocrinology & Metabolism (1997); Chapman IM. et al., Journal of Clinical Endocrinology & Metabolism (1997)

Areas of Scientific Research on Ipamorelin

Research on Muscle Mass and Lipolysis

Preclinical studies in rat models show that chronic administration of Ipamorelin is associated with an increase in muscle mass and a decrease in adipose tissue. These changes are attributed to increased GH secretion and the subsequent stimulation of IGF-1 production in the liver. IGF-1 is a key mediator of GH’s anabolic and lipolytic effects.
Ipamorelin’s selective profile (without cortisol or prolactin surges) makes the interpretation of research results regarding muscle mass less complicated compared to less selective GH secretagogues.

Gastrointestinal Research – Motility and Postoperative Ileus

A lesser-known but scientifically interesting property of Ipamorelin is its effect on gastrointestinal motility. GHS-R1a receptors are expressed not only in the pituitary gland but also in the gastrointestinal tract, where they play a role in regulating intestinal motility.
Preclinical studies in models of postoperative ileus (temporary cessation of peristalsis following surgery) demonstrate that ipamorelin accelerates the recovery of gastrointestinal motility compared to control groups. These results are the subject of further scientific investigation in the context of postoperative care.
Source: Poitras P. et al., Peptides (2005)

Technical Specifications

Parameter	Value
Chemical Name	Ipamorelin
Type	Synthetic pentapeptide
Amino acid sequence	Aib-His-D-2Nal-D-Phe-Lys-NH₂
Origin	Derived from GHRP-1
Molecular weight	711.9 Da
CAS Number	170851-70-4
Form	Lyophilized (freeze-dried) white powder
Contents per package	5 mg
Purity	≥ 98% (HPLC-verified)
Recommended storage conditions	−20 °C, protected from light and moisture
Stability (lyophilisate)	Up to 24 months at −20 °C
Stability (reconstituted)	Up to 28 days at 4 °C, up to 6 months at −20 °C
Intended Use	For scientific research purposes only

Frequently Asked Questions About Ipamorelin

What is Ipamorelin, and why is it considered a selective GH secretagogue?

Ipamorelin is a synthetic pentapeptide (5 amino acids) derived from GHRP-1 that acts as an agonist of the ghrelin receptor GHS-R1a. It is referred to in research as a “selective” GH secretagogue because preclinical studies consistently show that, unlike GHRP-2 and GHRP-6, it does not increase cortisol or prolactin levels. This selectivity allows researchers to study GH secretion in isolation.

What is the current state of research on the combination of Ipamorelin and CJC-1295?

Ipamorelin (a GHS-R1a agonist) and CJC-1295 (a GHRH analog) act on different receptors, producing a synergistic effect on GH secretion. Preclinical studies document an amplified GH pulse when both compounds are combined, compared to when they are administered separately. This combination is one of the most extensively studied in the field of GH peptides precisely because of its synergistic mechanism.

How does Ipamorelin differ from CJC-1295 (Modified GRF 1-29)?

Ipamorelin is a ghrelin receptor (GHS-R1a) agonist, while CJC-1295 and Modified GRF 1-29 are analogs of GHRH (Growth Hormone-Releasing Hormone) that act on the GHRH-R receptor. These are therefore two distinct classes of compounds with independent mechanisms of action that are being studied preclinically for their synergistic combination.

What is the purity of the Ipamorelin sold on jacked.sk?

Ipamorelin from jacked.sk has a purity of ≥98%, verified by HPLC (High-Performance Liquid Chromatography). Each batch is tested before shipment. A Certificate of Analysis (COA) is available upon request.

How should freeze-dried Ipamorelin be stored?

Store unopened packages at −20 °C, protected from light and moisture. After reconstitution with bacteriostatic water, store at 4 °C (for up to 28 days) or refreeze at −20 °C (for up to 6 months). We recommend using the dosing calculator to determine the exact amount of solvent.

Is Ipamorelin legal in Slovakia?

Ipamorelin is not listed as a controlled substance or a prohibited drug in the EU. In Slovakia, its purchase and possession for scientific research purposes are legal. Sales are intended exclusively for scientists and researchers. Jacked.sk sells Ipamorelin solely for scientific and research purposes, not for human use.

⚠️ Warning – Intended exclusively for research purposes

All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes. They are not intended for use as a medicine, drug, dietary supplement, or cosmetic product, nor for human or veterinary use. The results cited in the descriptions are based on preclinical studies (in vitro, animal models) and cannot be automatically extrapolated to human use. Sale restricted to individuals over the age of 18. By purchasing this product, the customer confirms that they are a professional researcher and will use the product solely in accordance with applicable laws.